2026-04-13T07:31:14Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1726482026-01-27T05:37:29Zcom_2072_1057col_2072_478916col_2072_478917

urn:hdl:2445/172648 Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Juric, Dejan Rodon, Jordi Tabernero Caturla, Josep Janku, Filip Burris, Howard A. Schellens, Jan H. M. Middleton, Mark R. Berlin, Jordan Schuler, Martin Gil-Martín, Marta Rugo, Hope S. Seggewiss Bernhardt, Ruth Huang, Alan Bootle, Douglas Demanse, David Blumenstein, Lars Coughlin, Christina Quadt, Cornelia Baselga Torres, Josep, 1959-2021 Càncer de mama Tiazoles Assaigs clínics Breast cancer Thiazoles Clinical trials PurposeWe report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase (PI3K)-selective inhibitor.Patients and MethodsIn the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily.ResultsOne hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses 270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes ( 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).ConclusionAlpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3K inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors. 2020-12-09T16:40:33Z 2020-12-09T16:40:33Z 2018-01-01 2020-12-02T14:17:46Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.7107 Journal of Clinical Oncology, 2018, vol. 36, num. 13, p. 1291-1299 https://doi.org/10.1200/JCO.2017.72.7107 (c) American Society of Clinical Oncology, 2018 info:eu-repo/semantics/openAccess Amer Soc Clinical Oncology Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))